Under what conditions can patients with superficial-vein thrombosis self-inject Arixtra (fondaparinux sodium) 1.5 mg/0.3 ml?

Patients with superficial-vein thrombosis may self-inject Arixtra (fondaparinux sodium) 1.5 mg/0.3 ml if judged willing and able and given clear instructions by a physician; the 1.5 mg once-daily dose is for creatinine clearance 20–50 ml/min, and its safety and efficacy have not been studied.